

May 23, 2022

REIG JOFRE LAUNCHES **REGENAIL**® TOPICAL SOLUTION FOR STRUCTURAL NAIL ALTERATIONS



Barcelona (Spain), REIG JOFRE, (BME:**RJF**) pharmaceutical company listed on the Spanish stock exchange, launches a new topical development for structural and aesthetic nail alterations. RegeNail® is the first product of the **CicloTech**® platform, advanced and patented trans-ungual release technology, result of public-private collaborative innovation between REIG JOFRE team and the Department of Pharmacy and Pharmaceutical Technology of the University of Santiago de Compostela.

Isabel Amat, Director of Innovation of Reig Jofre "The new product of the *Specialty Pharmacare* Business Unit is a good example of collaborative innovation, a model that Reig Jofre applies as innovation strategy. Open innovation is a lever for the development of new products with a differentiated and exclusive value proposition".

The new CicloTech® technology incorporates cyclodextrins as agents that promote the solubility of active ingredients, increasing hydration and facilitating faster healthy nail growth. Crossing the nail plate and achieving sufficient concentrations of active ingredients throughout the nail plate is the main challenge to be solved in topical nail treatment.

Joaquín García-Agustí, Director of the *Specialty Pharmacare* Business Unit "At Reig Jofre we are committed to health care in dermatology with advanced solutions at the service of the patient. These types of alterations of the nail plate are one of the most recurrent consultations in dermatology, whose European market amounts to 60 million euros. The development of innovative products and their potential internationalization are strategic pillars of growth"

The new product Regenail, manufactured at the Barcelona plant, is initially launched in Spain through its specialized network of medical representatives, although it is also planned to be marketed through the company's subsidiaries mainly in Europe and in the rest of the international markets through its network of business partners.

REIG JOFRE'S dermatology area represented 40% of the *Specialty Pharmacare* division sales in 2021, which together with the osteoarticular range reached sales of 75.5 million euros, with a growth of 14%, compared to the previous year.

REIG JOFRE achieved sales of €236 million and EBITDA of €27.3 million in 2021. The *Pharmaceutical Technologies* (antibiotics and injectables) *Specialty Pharmacare* (osteoarticular and dermatology) and *Consumer Healthcare* divisions accounted for 44%, 32% and 24 %, respectively. REIG JOFRE has subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore) and 155 commercial partners in more than 70 countries.

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com

www.reigjofre.com